Published in Curr Breast Cancer Rep on September 01, 2011
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med (1997) 13.96
Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol (2009) 3.50
Variation of breast cancer risk among BRCA1/2 carriers. JAMA (2008) 3.30
Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol (2011) 3.22
Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet (2002) 3.04
Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA (2000) 2.58
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2009) 2.47
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer (2006) 2.41
Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys (2003) 2.28
Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol (2010) 2.12
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol (2010) 1.85
Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res (2010) 1.70
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2011) 1.51
Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila) (2010) 1.35
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat (2010) 1.11
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat (2010) 1.10
Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2011) 0.92
Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status. Breast Cancer Res Treat (2010) 0.83